10-Q quarterly report · filed Nov 4, 2026

Outset Medical, Inc. (OM) Q3 2026 10-Q Quarterly Report

Short answer

Outset Medical, Inc. (OM) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $34M (up 14.2% year over year) with net income of −$15M.

Q3 2026 key financials · XBRL

Revenue
$34M
+14.2% YoY · +6.2% QoQ
Net income
−$15M
+17.7% YoY · +18.3% QoQ
Operating margin
-36.5%
Gross margin
40.7%
EPS (diluted)
−$0.78
+2.5% YoY · +19.6% QoQ

Source: XBRL data from the Outset Medical, Inc. (OM) Q3 2026 10-Q on SEC EDGAR. USD.

Outset Medical, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $33.6M, up 14% YoY from $29.4M, driven by product revenue up 15% to $23.7M
  • Gross margin 40.7% vs 39.4% YoY, with service and other revenue up 12% to $9.9M
  • Operating loss $12.3M vs $15.8M YoY, net loss $14.7M vs $17.8M
  • Cash, restricted cash and short-term investments $140.7M; nine-month operating cash outflow $32.9M
  • Near-term losses expected; customer purchase deferrals, tariffs, policy uncertainty and cautious capital spending remain headwinds

Risk Factors

  • New FDA Form 483 triggered by Q3 2026 San Jose inspection, citing CAPA, complaint handling, change documentation and data analysis
  • Regulatory compliance risk: unresolved FDA observations could bring further communications or official action
  • Operational risk: supplier noncompliance could disrupt timely production and required product quantities
  • Product risk: unanticipated adverse events could trigger labeling changes, restrictions or recalls
  • Financial risk: continued FDA remediation costs and management time may be significant

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Outset Medical, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.